Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.